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Antimicrobial and Healing Efficacy of Sustained
Release Nitric Oxide Nanoparticles Against
Staphylococcus Aureus Skin Infection
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Phil Gialanella4, Adam J. Friedman3,5,7, Joshua D. Nosanchuk1,2,7 and Joel M. Friedman3,7
Staphylococcus aureus (SA) is a leading cause of both superficial and invasive infections in community and
hospital settings, frequently resulting in chronic refractory disease. It is imperative that innovative therapeutics
to which the bacteria are unlikely to evolve resistance be developed to curtail associated morbidity and
mortality and ultimately improve our capacity to treat these infections. In this study, a previously unreported
nitric oxide (NO)-releasing nanoparticle technology is applied to the treatment of methicillin-resistant SA
(MRSA) wound infections. The results show that the nanoparticles exert antimicrobial activity against MRSA
in a murine wound model. Acceleration of infected wound closure in NO-treated groups was clinically shown
compared with controls. The histology of wounds revealed that NO nanoparticle treatment decreased
suppurative inflammation, minimal bacterial burden, and less collagen degradation, providing potential
mechanisms for biological activity. Together, these data suggest that these NO-releasing nanoparticles have
the potential to serve as a novel class of topically applied antimicrobials for the treatment of cutaneous
infections and wounds.
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INTRODUCTION
Staphylococcus aureus (SA) is an immotile Gram-positive
coccus that frequently colonizes human nasal membranes
and skin. This bacterium is responsible for the majority of
superficial and invasive skin infections, resulting in more than
11,000,000 outpatient/emergency room visits and 464,000
hospital admissions annually in the United States (Daum,
2007). Furthermore, certain SA clinical strains have recently
evolved resistance to vancomycin, an antibiotic to which
staphylococci have been uniformly sensitive. Although the
vancomycin-resistant strains remain rare, methicillin-resistant
strains (methicillin-resistant SA, MRSA) are increasingly
common (Hiramatsu et al., 1997), highlighting the urgent
need to develop new approaches for the treatment of SA
infections.
Topically applied nitric oxide (NO) is a potentially useful
preventive and therapeutic strategy against superficial skin
infections, including MRSA infections (Ghaffari et al., 2006).
NO modulates immune responses (Mowbray et al., 2009) and
is a significant regulator of wound healing (Soneja et al.,
2005). We have recently developed an inexpensive, stable,
and rapidly deployable NO-releasing platform using silane
hydrogel-based nanotechnology (Friedman et al., 2008). The
sustained release rate and total concentration of NO can be
modulated by altering the methods for nanoparticle produc-
tion, for example, by changing the molecular weight of
polyethylene glycol or the concentration of nitrite encapsu-
lated. Moreover, our platform benefits from the presence of
chitosan, which has been shown to have a potent anti-
microbial activity against bacteria (Rabea et al., 2003; Qi
et al., 2004). This natural polymer derived from crustacean
exoskeletons binds to and disrupts the cell wall and the
membrane of microorganisms because of its cationic charge
in weakly acidic environments.
In this study, we investigate the applicability of topically
applied NO through nanoparticles (NO-np) to SA skin
infections. On the basis of our earlier work (Friedman et al.,
2008), we hypothesized that NO-np can be microbicidal to
bacteria in an in vivo setting. To validate this hypothesis, we
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investigated the biological effect of NO-np on SA using a
mouse infection model.
RESULTS
Detection of NO-np release using amperometric analysis
Amperometric analysis revealed immediate NO release after
the addition of NO-np to the solution (Figure 1). The
observed trace indicates a relatively stable rate of NO
release with only a slight initial peak at 70minutes. A
steady-state level was achieved after 6 hours, maintained for
9 hours, and ongoing release occurred for B24 hours (data
not shown). Transmission electron microscopy reveals that
the individual NO-nps are B10 nm in diameter (Figure 1;
inset).
Staphylococcus aureus is susceptible to NO-np
We determined the susceptibility of clinical MRSA and MSSA
(methicillin-sensitive SA) strains to NO-np. The minimum
inhibitory concentration range for NO-np against 11 MRSA
strains was 312–2,500 mgml1 (corresponding to 4.69 nM
NO for the initial peak; 3.125 nM for steady state to 37.5 nM
for the initial peak; 25 nM for steady state), whereas the
range for NO-np for 9 MSSA strains was 312–1,250mgml1
(4.69 nM NO for the initial peak; 3.125 nM for steady state
to 18.75 nM for the initial peak; 12.5 nM for steady state)
(Table 1).
SA damage caused by NO-np was monitored by
transmission electron microscopy (Figure 2). Unexposed
bacteria showed uniform density in cytoplasmic compart-
ments and cell separation by a cross-wall surrounding a
highly contrasting splitting system (Figure 2a). After NO-np
treatment, the cross-wall began to disappear (1 hour after
treatment; Figure 2b) and cellular edema was visible (4 hours;
Figure 2c), followed by the destruction of cell wall
architecture (7 hours; Figure 2d) and subsequent cell lysis
(24 hours; Figure 2e).
NO increased wound-healing rate in mice
The effect of NO-np on wound healing in Balb/c mice was
investigated (Figure 3a and b). Application of NO-np
ectopically onto wounds decreased the size of eschar
significantly (Figure 3b). At day 3, the size of eschar of
uninfected or MRSA-infected wounds treated with NO-np
reached B2.75mm, whereas the size of eschar of untreated
or nanoparticles only (np particles containing the same
formulation as NO-np, but without NO precursor or
release) treated wounds was B4mm for the uninfected
groups (Po0.05) and B5.5mm in the MRSA-infected
untreated or np-treated groups (Po0.001; as compared
with NO-np treated groups). At day 7 (Figure 3b), the size
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Figure 1. Amperometric real-time detection of NO-np released. Kinetics of
nitric oxide (NO) release in solution was measured using amperometric
analysis. The inset TEM photograph shows uniform nitric oxide through
nanoparticles (NO-np) of B10 nm in diameter. Bar¼100 nm.
Table 1. Susceptibility of Staphylococcus aureus to
commonly used antimicrobial drugs and nitric oxide
Organism and antimicrobial agent n Range (lgml1) % S1
S. aureus MRSA 11
Ciprofloxacin p0.5–X8 27.3
Clindamycin p0.25–X8 54.6
Erythromycin p0.25–X8 18.2
Gentamicin p0.5–8 72.8
Oxacillin X4 0
Penicillin-G X0.5 0
Rifampin p0.5–1 0
Tetracycline p1–X16 90.9
Trimethoprim/Sulfa p10–X320 90.9
Vancomycin p1–2 100
Levofloxacin p0.125–X8 27.3
Quinupristin/Dalfopr p0.25–0.5 100
Nitrofurantoin p16–32 100
Linezolid 1–2 100
Moxicloxacin p0.25–X8 63.6
Nitric Oxide 312–25002 100
S. aureus MSSA 9
Ciprofloxacin p0.5–X8 88.9
Clindamycin p0.25 100
Erythromycin p0.25–0.5 100
Gentamicin p0.5 100
Oxacillin p0.25–0.5 100
Penicillin-G 0.125–X0.5 0
Rifampin p0.5 100
Tetracycline p1–X16 88.9
Trimethoprim/Sulfa p10 100
Vancomycin p1 100
Levofloxacin p0.125–X8 88.9
Quinupristin/Dalfopr p0.25–0.5 100
Nitrofurantoin p16–64 100
Linezolid 2 100
Moxicloxacin p0.25–2 100
Nitric oxide 312–12502 100
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-
sensitive Staphylococcus aureus.
1Percentage of isolates susceptible based on Clinical and Laboratory
Standards Institute guidelines.
25,000 mgml1 is equal to 75 nM in solution for initial peak; 50 nM in
solution for steady state.
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of eschar of the wounds of groups treated with NO-np was
B2mm, whereas the size of eschar of untreated or np-treated
wounds reachedB3mm for the uninfected groups (Po0.05)
and B4.5mm for the MRSA-infected untreated or np-treated
groups (Po0.01).
NO killed MRSA in superficial skin lesions
The efficacy of NO-np in killing SA in mice was further
explored by examining the bacterial burden in these
skin infections. Four days after infection, wounds were
swabbed and plated on tryptic soy agar. MRSA-infected
NO-np-treated wounds showed significantly lower microbial
burden than did the untreated or np-treated wounds (Po0.01)
(Figure 4a). Furthermore, to confirm percutaneous bacterial
penetration of the epidermal tissue and to show the efficacy of
NO in controlling bacterial infection, the infected skin tissue
was removed from mice that were killed at day 7 after
infection and the bacterial burden determined. MRSA-infected
Figure 2. NO-releasing nanoparticles have antimicrobial activity against SA. TEM of SA exposed to sustained release of NO by nanoparticles revealed cell wall
damage and lysis. (a) Growth of SA in the absence of NO-np showed intact cell wall architecture (control). Growth of SA in the presence NO-np after 1 (b), 4 (c),
7 (d), and 24hours (e) showed increasing destruction of cell wall architecture, edema, and cell lysis. White and black arrows denote bacterial cross-wall and cell
wall damage after NO treatment, respectively. Bar¼ 0.2 mm.
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Figure 3. NO-np increased the wound healing rate in mice. (a) Wounds of Balb/c mice uninfected and untreated, uninfected treated with nanoparticles
without nitric oxide (NO) (np), uninfected treated with nitric oxide through nanoparticle (NO-np,) untreated methicillin-resistant Staphylococcus aureus
(MRSA)-infected, np-treated MRSA-infected, and MRSA-infected treated with NO-np, days 3 and 7. Bar¼ 5mm. (b) Wound size analysis of Balb/c mice skin
lesions. Wounds were uninfected or infected with MRSA and untreated or treated in the absence or presence of NO. Time points are the averages of the results
for ten measurements, and error bars denote SDs. *Po0.05 in comparing the NO-treated groups with uninfected or MRSA-infected and untreated groups.
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mice treated with NO-np had significantly lower microbial
burden than did the untreated or np-treated mice (Po0.01)
(Figure 4b). In both assays, o30 colony forming units (CFUs)
were detected in the skin of uninfected mice and SA was not
identified.
Histological examinations revealed that wounds of un-
treated or np-treated uninfected mice had intense inflamma-
tory infiltrate in the absence of bacteria by Gram stains
(Figure 4c). Analysis of MRSA-infected wounds, both
untreated and np-treated, showed an even more severe
neutrophil-rich infiltrate along with extensive cell necrosis.
Tissue Gram stains of these samples revealed large numbers
of Gram-positive cocci (Figure 4c; insets). Tissue sections
from the wounds of NO-np-treated uninfected mice and
MRSA-infected mice revealed less suppurative inflammation
along with increased fibrin deposition and no evidence of
bacteria (Figure 4c).
NO-np enhances wound healing by preventing MRSA collagen
degradation
The mechanisms through which the NO-nps accelerate
wound healing were further determined by establishing
whether NO-nps prevented collagen degradation by MRSA
in the infected tissue. Collagen content was highest in
both uninfected and infected wounds treated with
NO-nps, although np-treated uninfected tissue also had
high collagen content (Figure 5a). The dispersed blue
stain indicated thicker and more mature tissue collagen
formation in wounds treated with NO-np, suggesting that
NO-np exposure maintained dermal architecture through
bacterial clearance, and ultimately by guarding collagen.
Figure 5b is a morphometric analysis of the data shown in
Figure 5a.
DISCUSSION
Many investigations have suggested the important role of NO
in immunity and the wound-healing process, and therefore
the potential applications are broad and the implications
multidisciplinary. With respect to this study, the nanoparti-
culate powder could be used in the treatment of numerous
types of wounds, such as burns and decubiti. Furthermore,
wound healing complicated by common comorbidities, such
as obesity, diabetes, atopic dermatitis, and peripheral
vascular disease may benefit from an NO-based therapeutic.
Specifically, diabetics are prone to chronic leg and foot
ulcerations caused by abnormalities in NO production
resulting in both neurological and vascular complications
(Honing et al., 1998). The avascular nature of these wounds
and the colonization/infection of resistant bacterial species
have undermined the efficacy of conventional treatments and
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Figure 4. NO-np killed MRSA in superficial skin lesions. (a) Wound bacterial burden (CFU; colony forming unit) in NO-treated mice infected intradermally
with 107 methicillin-resistant Staphylococcus aureus is significantly lower than untreated or NP-treated mice (n¼ 10 per group). Four days after infection,
wounds were swabbed and bacteria burden examined. (b) Seven days after infection, infected skin tissue was removed from mice and bacterial burden
determined. Uninfected mice untreated, NP-, and NO-treated were used as a control. Bars are the averages of the results for three measurements, and error bars
denote standard daviations. Asterisks denote P-value significance (**Po0.01) calculated by analysis of variance and adjusted by use of the Bonferroni
correction. (c) Histological analysis of BALB/C mice uninfected and untreated, uninfected treated with nanoparticles without NO (NP), uninfected treated
with NO-NP (NO), untreated MRSA-infected, NP-treated MRSA-infected, and MRSA-infected treated with NO, day 7. Mice were infected with 107 MRSA
bacterial cells. Representative H&E-stained sections of the skin lesions are shown with the insets representing Gram staining specific for MRSA cells (shown
in purple). Scale bars ¼ 25 mm.
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also underscored the need for a previously unreported
therapeutic approach, such as the sustained delivery of NO,
as addressed in this study.
We showed that the beneficial effect of the NO-np
treatment on wound closure is likely because of antimicrobial
activity and the promotion of collagen deposition. In wound
healing, collagen synthesis can be correlated with fibroblast
proliferation and differentiation (Schaffer et al., 1996).
However, with regard to these findings, it is possible that
pre-existing collagen in the wound bed may have limited the
precision of our analysis. Therefore, we are pursuing further
in-depth investigations of these observations through specific
markers of re-epithelization, such as pro-collagen and elastin,
and markers of angiogenesis, such as CD31.
With regard to this specific NO delivery platform, the
stability of the compound combined with the simplicity of
treatment makes NO-nps ideal for combat or disaster
situations; soldiers or emergency personnel could carry
packets with NO-np and topically apply it to traumatic
wounds in the field to combat microbial infections before
receiving expert medical care. Topically applied NO has
been effective in inducing a local immune response with
minimal inflammation (Mowbray et al., 2009), further adding
to its beneficial effects in this application.
With regard to safety and toxicity, the cytotoxic potential
for nanotechnologies has been well documented and widely
commented on (Service 2003; Nel et al., 2006). Numerous
investigations have revealed that diverse nanomaterials can
penetrate intact skin in animal models and in human ex vivo
models (Chang et al., 2006; Gamer et al., 2006; Baroli et al.,
2007). Furthermore, cutaneous penetration can be enhanced
depending on the delivery vehicle or barrier disruption,
especially in cases of open wounds, such as those that we
describe in this study. Of greater concern, toxicities caused
by the systemic penetration and ultimate circulation of
specific nanomaterials through various orifices have been
shown (Afaq et al., 1998; Hohr et al., 2002). We have shown
in vitro that NO-nps show minimal toxicity toward cultured
fibroblasts (Friedman et al., 2008). Furthermore, in vivo safety
(murine) evaluation through intraperitoneal and intravenous
administration revealed minimal serologically determined
cytotoxicity and no clinical adverse events (Cabrales P,
personal communication).
In summary, the presented data show that NO-nps have
both antimicrobial and wound-healing properties. Overall,
the presented results show that the topical application of NO-
nps is highly effective against cutaneous MRSA infection in a
murine model. In addition, the NO-nps appear to enhance
wound healing by shielding dermal structural components,
such as collagen from degradation. These results suggest that
this platform has the potential to serve as a previously
unreported, to our knowledge, easily administered class of
topical antimicrobials for the treatment of cutaneous infec-
tions and wounds.
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Figure 5. NO-nps decrease collagen degradation in skin lesions of Balb/c mice. (a) Histological analysis of Balb/c mice uninfected and untreated (Untr),
uninfected treated with nanoparticles without nitric oxide (NO) (np), uninfected treated with NO-nps (NO), untreated methicillin-resistant Staphylococcus
aureus (MRSA)-infected, np-treated MRSA-infected, and MRSA-infected treated with NO, day 7. Mice were infected with 107 bacterial cells. The blue
stain indicates collagen. Bar ¼ 25 mm. (b) Quantitative measurement of collagen intensity in 16 representative fields of the same size for uninfected and
untreated, uninfected treated with nanoparticles without NO (np), uninfected treated with NO, untreated MRSA-infected, np-treated MRSA-infected, and
MRSA-infected treated with NO wounds. Bars are the averages of the results, and error bars denote SDs. *Po0.01 in comparing the untreated groups with
the uninfected np- and NO-treated groups; **Po0.001 in comparing the untreated groups with the MRSAþNO group.
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MATERIALS AND METHODS
SA clinical isolates
The SA clinical isolates used in this study were collected from
patients’ wounds at the Montefiore Medical Center, Bronx, NY. All
samples were obtained with the written consent of all patients
according to the practices and standards of the institutional review
boards at the Albert Einstein College of Medicine and Montefiore
Medical Center. In addition, all studies were conducted according to
the Declaration of Helsinki Principles. A total of 20 clinical isolates
were studied, including 11 MRSA and 9 MSSA strains, which were
stored in a BHI broth (BBL, Cockeysville, MD) containing 40%
glycerol at 80 1C until use, and then were grown in a Tryptic Soy
broth (TSB; MP Biomedicals, LLC, Solon, OH) overnight at 37 1C
with rotary shaking at 150 r.p.m. Their growth was monitored by
measuring the optical density at 600nm (Bio-Tek, Winooski, VT).
Synthesis of NO-np
The synthesis of NO-np was recently reported along with its
potential as a treatment for superficial infections (Friedman et al.,
2008). Briefly, a hydrogel/glass composite was synthesized using a
mixture of tetramethylorthosilicate, polyethylene glycol, chitosan,
glucose, and sodium nitrite in a 0.5 M sodium phosphate buffer (pH
7). The nitrite was reduced to NO within the matrix because of the
glass properties of the composite effecting redox reactions initiated
with thermally generated electrons from glucose. After redox
reaction, the ingredients were combined and dried using a
lyophilizer, resulting in a fine powder comprising nanoparticles
containing NO. Once exposed to an aqueous environment, the
hydrogel properties of the composite allow for an opening of
the water channels inside the particles, facilitating the release of the
trapped NO over extended time periods.
Amperometric detection of NO release
Amperometric detection of NO released from the nanoparticles was
achieved using the Apollo 4000 Nitric Oxide Detector (World Precision
Instruments, Sarasota, FL). The system is based on a composite graphite
NO-sensing element coated with an NO-selective membrane coupled
with a reference electrode and can sense NO levels down to the
subnanomolar range (Zhang and Broderick, 2000). Out of numerous
sensor tips, the ISO-NOP sensor (World Precision Instruments Ltd.,
Sarasota, FL) was used because of its detection limits (1nM minimum),
quick response time, and specificity toward NO. Briefly, argon degassed
0.05M phosphate buffer was saturated with NO gas, resulting in a
1.9mM solution of NO. The probe on the NO detector system was
allowed to equilibrate with 20ml of 0.05M phosphate buffer under
stirring. Aliquots of the saturated NO solution were added and the
resulting data were used to construct a linear calibration curve. Data
were generated by allowing the system to equilibrate with 20ml of
0.05M phosphate buffer under stirring and then adding 100mg of NO-
np. Data were then collected over time and correlated with the
calibration data, resulting in measurements of NO concentration in
solution over time.
Susceptibility of MRSA and MSSA strains to NO-np
To evaluate the susceptibility of SA to NO-np, a suspension of
107 SA cells were incubated in an Eppendorf tube with 1ml of
DMEM (Mediatech, Herndon, VA) containing NO-np (0.313, 0.625,
1.25, 2.5, or 5mgml1). A tube containing bacteria with DMEM
alone was used as a control. Bacteria and nanoparticles were
constantly mixed using a tube rotator (ATR, Laurel, MD) to
ensure uniform distribution and incubated at 37 1C for 2 hours.
CFU counts were assessed to determine the toxicity of NO on
bacterial mass. After incubation with NO-np, a volume of 100 ml of
suspension containing bacteria was aspirated and transferred into
another Eppendorf tube with 900 ml of phosphate-buffered saline
(PBS), and vortexed gently. The suspensions were serially diluted in
PBS and aliquots were plated on tryptic soy agar plates. The
percentage of CFU survival was determined by comparing the
survival of NO-treated SA cells relative to the survival of untreated
bacteria.
NO treatment and skin infection
Skin and soft tissue are the most common sites of SA infection and
comprise more than 75% of MRSA disease. To simulate this pattern
of SA exposure, the hair on the back of female Balb/c mice
(6–8 weeks; National Cancer Institute, Frederick, MD) was shaved
and the skin disinfected with ethanol. Single punch biopsies were
performed on the back of the mice, resulting in 5-mm diameter full-
thickness excision wounds. Thereafter, a suspension containing 107
SA 6498 in PBS was inoculated directly onto the wound and 5mg of
the lyophilized NO-np or np powder was topically applied 1 and
72 hours after biopsy. SA 6498 is a clinical isolate that was selected
for this experiment, because the strain is resistant to diverse
commonly used antibiotics. Untreated mice were used as an
additional control. Photographs of the wounds were taken daily to
follow gross visual wound healing as assessed by the area of the
wound uncovered by the migrating epithelia. On day 7 after biopsy,
mice were killed and histological sections of the wound area were
obtained for analysis.
Histological processing of skin infection model
On day 7 after MRSA inoculation, skin lesion tissues were excised
from mice that were killed, fixed in 10% formalin for 24 hours,
processed, and embedded in paraffin. Four-micron vertical sections
were fixed to glass slides, hematoxylin and eosin, Gram, or Masson’s
trichrome stained to observe the morphology, bacteria, or collagen
deposition, respectively, and examined using light microscopy.
The CFU determinations are:
(i) Superficial examination. At day 4 after MRSA inoculation, a
wet swab with sterile PBS was applied superficially to the
wounds of the mice and plated on tryptic soy agar.
(ii) Wound examination. At day 7 after MRSA inoculation, skin
lesion tissues were homogenized in sterile PBS and plated on
tryptic soy agar.
Eschar size analysis using a mouse skin infection model
Ten mice in each group were examined. Wound size analysis was
performed on days 3 and 7 after initial surgery. Histological sections
were prepared, and the maximal diameter of each eschar was
measured using light microscopy.
Transmission electron microscopy
Transmission electron microscopy was used to visualize NO-np and
SA. Samples were fixed in 2.5% glutaraldehyde in 0.1 M cacodylate
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buffer at room temperature for 2 hours and then incubated overnight
in 4% formaldehyde, 1% glutaraldehyde, and 0.1% PBS. The samples
were incubated for 90minutes in 2% osmium tetroxide, serially
dehydrated in ethanol, and embedded in Spurr’s epoxy resin. Thin
sections were obtained on a Reichert Ultracut (Austria) and stained
with 0.5% uranyl acetate and 0.5% lead citrate. Samples were
observed in a JEOL 1200EX transmission electron microscope (JEOL
Ltd., Tokyo, Japan) operating at 80kV.
Statistical analysis
All data were subjected to statistical analysis using GraphPad Prism
5.0 (GraphPad Software, La Jolla, CA). P-values were calculated by
analysis of variance and were adjusted by use of the Bonferroni
correction. P-values of o0.05 were considered significant.
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